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Noninvasive ventilation (NIV) is now an established 
evidence-based treatment for acute hypercapnic 
respiratory failure (AHRF), predominantly for defined 
patients admitted with exacerbations of chronic 
obstructive pulmonary disease (COPD), but also 
a range of other conditions including obesity-
related respiratory failure and chest wall deformities 
requiring an acute hospital admission. Over the 
past two decades, there has been a significant 
shift towards greater use of NIV in place of invasive 
mechanical ventilation (IMV) in this group of 
patients. Here we set out to discuss a landmark 
paper in this respect: the report of the YONIV trial 
(Yorkshire Noninvasive Ventilation Trial), published 
in June 2000, which addressed the key practical 
questions around the early use of ward-based NIV 
at the time [1]. A recent narrative review on the 
epidemiology of NIV for acute respiratory failure 
in COPD patients concluded that this dramatic 
increase in NIV use is probably due to the increased 
experience of the medical teams, treating sicker 
patients with comorbidities and utilising NIV outside 
the intensive care unit (ICU), further confirming the 
pivotal role of the original trial enabling the early 
use of acute NIV on medical wards [2].
The 1990s question: is NIV 
feasible in the “real world”?
Evidence about the effect of noninvasive positive 
pressure ventilation, particularly in exacerbations 
of COPD, has been accumulating since the early 
1990s. NIV was shown to improve the hypercapnic 
ventilatory response (respiratory drive), improve 
gas exchange, reduce the work of breathing and 
unloading inspiratory muscles [3, 4].
However, there remained a big question about 
the wider applicability of NIV in the “real world”, 
i.e. outside centres with considerable expertise in 
respiratory physiology. The initial response was 
seen to be good, but the 30-day mortality did not 
show a significant improvement [5]. Also, there were 
concerns that application of NIV in the emergency 
department may delay tracheal intubation and the 
initiation of mechanical ventilation in some patients 
with acute respiratory distress. The logistical problem 
of assessing patients for encephalopathy, agitation 
and loss of alertness while they wore nasal masks 
was thought to have contributed to a delay in the 
clinical recognition of the need for intubation [6].
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The 1990s question: can NIV 
be performed successfully 
outside the ICU?
The evidence for the successful use of NIV in ICU 
patients with acute exacerbations of COPD to 
avoid endotracheal intubation and complications 
associated with IMV was steadily firming up in the 
1990s. Patients enrolled in such studies had known 
COPD, or a high probability of the disease (on the 
basis of the clinical history, physical examination 
and chest film), with respiratory acidosis and an 
elevated bicarbonate level. It was being established 
that in selected patients with acute exacerbations 
of COPD (in the ICU), NIV can reduce the need for 
endotracheal intubation, the length of the hospital 
stay, and the in-hospital mortality rate [7]. However, 
the availability of ICU beds varies from country to 
country and it was increasingly being acknowledged 
that the inability to use NIV on general wards could 
delay its use and that even a short delay might make 
NIV fail.
The YONIV trial: early ward-
based acute NIV
The YONIV trial aimed to find out whether the 
introduction of NIV, early after the admission to a 
general respiratory ward, was effective at reducing 
the need for intubation and the mortality associated 
with acute exacerbations of COPD [1]. It was a 
prospective, multicentre randomised controlled 
study (involving 14 UK hospitals over 22 months) 
comparing NIV with standard therapy in patients 
with mild-to-moderate acidosis during an acute 
exacerbation of COPD. NIV was administered on 
the ward with a simple noninvasive ventilator and 
a standardised predefined protocol. A total of 236 
patients were recruited, 118 received standard 
therapy alone and 118 received additional NIV. The 
two groups had similar characteristics at enrolment. 
The use of NIV significantly reduced the need for 
intubation as defined by the failure criteria. 32 
(27%) out of 118 patients in the standard therapy 
group failed compared with 18 (15%) patients in the 
NIV group (p=0.02). In-hospital mortality was also 
reduced by NIV: 24 (20%) out of 118 patients died in 
the standard group compared with 12 (10%) out of 
118 in the NIV group (p=0.05). In both groups, the 
pH, arterial carbon dioxide tension and respiratory 
rate improved at 4 h (p<0.01). However, NIV led to 
a more rapid improvement in pH in the first hour 
(p=0.02) and a greater fall in respiratory rate at 4 h 
(p=0.035). The duration of breathlessness was also 
reduced by NIV (p=0.025).
This trial directly addressed the two biggest 
questions the respiratory and critical care 
community faced at the time: “is NIV feasible in the 
real world?” and “can NIV be performed successfully 
outside the ICU?”. It demonstrated that the early use 
of NIV for mildly and moderately acidotic patients 
with COPD in a general ward setting leads to more 
rapid improvement of physiological variables, 
a reduction in the need for IMV (with objective 
criteria), and a reduction in in-hospital mortality.
Summary and prospect
Early ward-based NIV has been the bedrock for the 
expansion of acute NIV services across countries. 
15 years after the publication of YONIV, an 
international survey including a sample of hospitals 
from five continents focusing on ward-based NIV 
for AHRF has shown that acute exacerbations of 
COPD are the most common indication for NIV 
use outside the ICU (94%) and that NIV outside 
the ICU has become a growing phenomenon [8]. 
Although patients can be extensively monitored in 
the “safe” ICU environment, a shortage of intensive 
care beds, managing less severe cases of AHRF in 
other units, and increased experience and evidence 
in the use of NIV outside the ICU may have led to 
this trend. The survey concluded that the use of 
NIV in general wards was effective, common and 
gradually increasing. Improvements in staff training 
and introduction of protocols could help to make 
this technique safer and more common when 
applied in a general ward setting [9, 10].
It has been shown that caring for a higher volume 
of NIV patients in ICU may develop local expertise 
and lead to better NIV outcomes [11]. We have seen 
similar effects of patient volume on local expertise 
when analysing temporal trends at a single, large 
ward-based NIV unit, recording that more severely 
ill acute hypercapnic respiratory failure patients are 
being treated with no significant change in mortality 
[12]. Ward-based NIV is consistently emerging as 
a sustainable tool to deal with acute exacerbations 
of COPD as well as other patients with ventilatory 
insufficiency leading to hospital admissions due to 
respiratory failure, who are now living longer with 
various comorbidities.
Even in the USA, where NIV was almost 
exclusively used in ICUs in the 1990s, an 
observational cohort study based at eight acute care 
hospitals in Massachusetts found that, although 
only a fifth of acute NIV patients were started on 
general wards, the NIV utilisation rate was highest 
for general wards (73%), most likely reflecting 
the higher proportion of patients with a “do-not-
intubate” status in general wards compared with 
critical care units [13].
In the context of limited availability of ICU beds, 
some clinicians may consider that admission of 
debilitated patients with an underlying end-stage 
chronic illness, like those with COPD, may merely 
deprive other critically ill candidates who could 
benefit more from ICU resources. So the question 
is no longer “should we use NIV in ‘do-not-intubate’ 
patients?”, the answer is obviously “Yes”, NIV should 
at least be offered to these patients, especially when 
the underlying cause of the AHRF is reversible, but 
rather “how can we apply NIV to ‘do-not-intubate’ 
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patients without drifting toward unreasonable 
care?”[14].
Finally, there is accumulating evidence of 
improved admission-free survival through 
administration of post-acute home nocturnal NIV 
in selected patients in the largest segment of acute 
NIV recipients (those with persistent hypercapnia 
following an acute exacerbation of COPD are the 
ones that benefit) [15]. The expansion of ward-
based NIV, enabled largely by YONIV and similar 
trials, is on the verge of seeing a step change in 
improving outcomes in people living with COPD.
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